免疫检查点抑制剂在治疗原发性肝癌中的研究进展
Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer
DOI: 10.12677/ACM.2022.124486, PDF,   
作者: 刘 军：重庆市璧山区第二人民医院普外科，重庆；李金昊, 龚建平*：重庆医科大学附属第二医院肝胆外科，重庆
关键词: 原发性肝癌；免疫治疗；程序性细胞死亡蛋白-1；细胞毒性T淋巴细胞相关抗原-4；Primary Liver Cancer； Immunity Therapy； PD-1； CTLA-4
摘要: 原发性肝癌是全球癌症相关性死亡的重要原因，其往往起病隐匿，发现时已发展至疾病中晚期。传统的靶向药物常常不能满足肝癌患者的临床需求，近年来，肿瘤免疫微环境受到越来越多的关注，免疫检查点抑制剂的出现，带给肝癌患者新的治疗选择。因此，国内外众多学者纷纷开始研究免疫检查点抑制剂的临床获益，相关的临床研究结果也给人以极大的鼓舞。因此，本文将对免疫检查点抑制剂的作用机制及其临床研究进展作一综述。
Abstract: Primary liver cancer is an important cause of cancer-related death worldwide, and its onset is often insidious, and it has progressed to the middle and late stages of the disease when it is detected. Traditional targeted drugs often cannot meet the clinical needs of liver cancer patients. In recent years, the tumor immune microenvironment has received more and more attention. The emergence of immune checkpoint inhibitors has brought new treatment options for liver cancer patients. Therefore, many scholars at home and abroad have begun to study the clinical benefits of immune checkpoint inhibitors, and the relevant clinical research results are also very encouraging. Therefore, this article will review the mechanism of action of immune checkpoint inhibitors and their clinical research progress.
文章引用：刘军, 李金昊, 龚建平. 免疫检查点抑制剂在治疗原发性肝癌中的研究进展[J]. 临床医学进展, 2022, 12(4): 3360-3366. https://doi.org/10.12677/ACM.2022.124486

参考文献

[1] McGlynn, K.A., Petrick, J.L. and El-Serag, H.B. (2021) Epidemiology of Hepatocellular Carcinoma. Hepatology, 73, 4-13. [Google Scholar] [CrossRef] [PubMed]
[2] Chidambaranathan-Reghupaty, S., Fisher, P.B. and Sarkar, D. (2021) Hepatocellular Carcinoma (HCC). Epidemiology, Etiology and Molecular Classification. Advances in Cancer Research, 149, 1-61. [Google Scholar] [CrossRef] [PubMed]
[3] Forner, A., Reig, M. and Bruix, J. (2021) Hepatocellular Carcinoma. The Lancet, 391, 1301-1314. [Google Scholar] [CrossRef] 
[4] Le Grazie, M., Biagini, M.R., Tarocchi, M., Polvani, S. and Galli, A. (2017) Chemotherapy for Hepatocellular Carcinoma. The Present and the Future. World Journal of Hepatology, 9, 907-920. [Google Scholar] [CrossRef] [PubMed]
[5] Rizell, M., Sternby Eilard, M., Andersson, M., Andersson, B., Karlsson-Parra, A. and Suenaert, P. (2019) Phase 1 Trial with the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 9, Article No. 19. [Google Scholar] [CrossRef] [PubMed]
[6] Bruix, J., Chan, S.L., Galle, P.R., Rimassa, L. and Sangro, B. (2021) Systemic Treatment of Hepatocellular Carcinoma. An EASL Position Paper. Journal of Hepatology, 75, 960-974. [Google Scholar] [CrossRef] [PubMed]
[7] Cheng, A.L., Hsu, C., Chan, S.L., Choo, S.P. and Kudo, M. (2020) Challenges of Combination Therapy with Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Journal of Hepatology, 72, 307-319. [Google Scholar] [CrossRef] [PubMed]
[8] Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., et al. (2018) Sorafenib Plus Low-Dose Cisplatin and Fluorouracil Hepatic Arterial Infusion Chemotherapy versus Sorafenib alone in Patients with Advanced Hepatocellular Carcinoma (SILIUS): A Randomised, Open Label, Phase 3 Trial. The Lancet Gastroenterology & Hepatology, 3, 424-432. [Google Scholar] [CrossRef] 
[9] Swann, J.B. and Smyth, M.J. (2007) Immune Surveillance of Tumors. Journal of Clinical Investigation, 117, 1137-1146. [Google Scholar] [CrossRef] 
[10] Shlomai, A., de Jong, Y.P. and Rice, C.M. (2014) Virus Associated Malignancies. The Role of Viral Hepatitis in Hepatocellular Carcinoma. Seminars in Cancer Biology, 26, 78-88. [Google Scholar] [CrossRef] [PubMed]
[11] Hato, T., Goyal, L., Greten, T.F., Duda, D.G. and Zhu, A.X. (2014) Immune Checkpoint Blockade in Hepatocellular Carcinoma. Current Progress and Future Directions. Hepatology, 60, 1776-1782. [Google Scholar] [CrossRef] [PubMed]
[12] Ruf, B., Heinrich, B. and Greten, T.F. (2021) Immunobiology and Immunotherapy of HCC. Spotlight on Innate and Innate-Like Immune Cells. Cellular & Molecular Immunology, 18, 112-127. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., et al. (2019) Current Perspectives on the Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma: Challenges and Opportunities. Molecular Cancer, 18, Article No. 130. [Google Scholar] [CrossRef] [PubMed]
[14] Shen, Y.C., Hsu, C.L., Jeng, Y.M., Ho, M.C., Ho, C.M., Yeh, C.P., et al. (2020) Reliability of a Single-Region Sample to Evaluate Tumor Immune Microenvironment in Hepatocellular Carcinoma. Journal of Hepatology, 72, 489-497. [Google Scholar] [CrossRef] [PubMed]
[15] Kim, E. and Viatour, P. (2020) Hepatocellular Carcinoma: Old Friends and New Tricks. Experimental & Molecular Medicine, 52, 1898-1907. [Google Scholar] [CrossRef] [PubMed]
[16] Zhai, Y., Moosavi, R. and Chen, M. (2021) Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 12, Article ID: 645699. [Google Scholar] [CrossRef] [PubMed]
[17] Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R. and Cheli, Y. (2021) Immune Checkpoints in Cancers: From Signaling to the Clinic. Cancers, 13, Article No. 4573. [Google Scholar] [CrossRef] [PubMed]
[18] Jacquelot, N., Ghaedi, M., Warner, K., Chung, D.C., Crome, S.Q. and Ohashi, P.S. (2021) Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers, 13, Article No. 5967. [Google Scholar] [CrossRef] [PubMed]
[19] Jansson, A., Barnes, E., Klenerman, P., Harlén, M., Sørensen, P., Davis, S.J., et al. (2005) A Theoretical Framework for Quantitative Analysis of the Molecular Basis of Costimulation. The Journal of Immunology, 175, 1575-1585. [Google Scholar] [CrossRef] [PubMed]
[20] Zou, W., Wolchok, J.D. and Chen, L. (2016) PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations. Science Translational Medicine, 8, 328rv4. [Google Scholar] [CrossRef] [PubMed]
[21] Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Hong, Y., Yagita, H., et al. (2010) Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization. The Journal of Immunology, 185, 5082-5092. [Google Scholar] [CrossRef] [PubMed]
[22] Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. [Google Scholar] [CrossRef] [PubMed]
[23] Toor, S.M., Sasidharan Nair, V., Decock, J. and Elkord, E. (2020) Immune Checkpoints in the Tumor Microenvironment. Seminars in Cancer Biology, 65, 1-12. [Google Scholar] [CrossRef] [PubMed]
[24] Crocenzi, T., Meyer, T., Melero, I., Yau, T., Hsu, C., Kudo, M., et al. (2018) Tu1483-Hepatic Safety and Biomarker Assessments in Sorafenib experienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study. Gastroenterology, 154, S-1234. [Google Scholar] [CrossRef] 
[25] El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef] 
[26] Adcock, C.S., Puneky, L.V. and Campbell, G.S. (2019) Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-Arterial Radioembolization Followed by Sorafenib and Nivolumab. Cureus, 11, e4083. [Google Scholar] [CrossRef] [PubMed]
[27] Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. [Google Scholar] [CrossRef] 
[28] Finn, R.S., Ryoo, B.Y., Merle, P., Kudo, M., Bouattour, M., Lim, H.Y., et al. (2020) Pembrolizumab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 38, 193-202. [Google Scholar] [CrossRef] 
[29] Lee, H.T., Lee, J.Y., Lim, H., Lee, S.H., Moon, Y.J., Pyo, H.J., et al. (2017) Molecular Mechanism of PD-1/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab. Scientific Reports, 7, Article No. 5532. [Google Scholar] [CrossRef] [PubMed]
[30] Tan, S., Liu, K., Chai, Y., Zhang, C.W., Gao, S., Gao, G.F., et al. (2018) Distinct PD-L1 Binding Characteristics of Therapeutic Monoclonal Antibody Durvalumab. Protein & Cell, 9, 135-139. [Google Scholar] [CrossRef] [PubMed]
[31] Kelley, R.K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.K., et al. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001. [Google Scholar] [CrossRef] 

为你推荐